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Edited by Roger ColbranThe role of lipids in modulating membrane protein function
is an emerging and rapidly growing area of research. The
rational design of lipids that target membrane proteins for the
treatment of pathological conditions is a novel extension in this
field and provides a step forward in our understanding of
membrane transporters. Bioactive lipids show considerable
promise as analgesics for the treatment of chronic pain and
bind to a high-affinity allosteric-binding site on the human
glycine transporter 2 (GlyT2 or SLC6A5). Here, we use a
combination of medicinal chemistry, electrophysiology, and
computational modeling to develop a rational structure–
activity relationship for lipid inhibitors and demonstrate the
key role of the lipid tail interactions for GlyT2 inhibition.
Specifically, we examine how lipid inhibitor head group ste-
reochemistry, tail length, and double-bond position promote
enhanced inhibition. Overall, the L-stereoisomer is generally a
better inhibitor than the D-stereoisomer, longer tail length
correlates with greater potency, and the position of the double
bond influences the activity of the inhibitor. We propose that
the binding of the lipid inhibitor deep into the allosteric-
binding pocket is critical for inhibition. Furthermore, this
provides insight into the mechanism of inhibition of GlyT2 and
highlights how lipids can modulate the activity of membrane
proteins by binding to cavities between helices. The principles
identified in this work have broader implications for the
development of a larger class of compounds that could target
SLC6 transporters for disease treatment.
One in 10 adults worldwide is diagnosed with chronic pain
each year (1). Despite the high rate of chronic pain, there is a
lack of safe and effective treatment options, which in turn has
significant social and economic consequences (2). In the
mammalian central nervous system, the neurotransmitter
glycine inhibits the pain-signaling pathway (3). Synaptic con-
centrations of glycine are controlled by the two glycine
transporters, GlyT1 and GlyT2, which are responsible forThis article contains supporting information.
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BY license (http://creativecommons.org/licenses/by/4.0/).clearing glycine from synapses (4). GlyT2 is expressed by
presynaptic neurons and is also responsible for replenishing
presynaptic glycine concentrations to maintain glycinergic
neurotransmission. Inhibitors of GlyT2 slow the reuptake of
glycine to prolong glycine neurotransmission (5) and have
been developed as potential therapeutics in the treatment of
chronic pain (6–11).
N-acyl amino acids that comprise an amino acid head group
conjugated via an amide bond to a monounsaturated lipid tail
represent a novel class of GlyT2 inhibitors (6). Our previous
studies have shown that despite the high level of sequence
conservation between GlyT2 and GlyT1, these compounds do
not inhibit GlyT1 (6, 12, 13). One of the most promising
bioactive lipids from this series, oleoyl D-lysine (C18ω9-D-Lys),
is a selective and potent GlyT2 inhibitor that is metabolically
stable, blood–brain barrier permeable, and produces analgesia
in a rat model of neuropathic pain with minimal side effects
(13). The reduced toxicity of these compounds is attributed to
partial inhibition of GlyT2. They reduce but do not completely
block glycine transport, which allows presynaptic glycine
concentrations to be maintained for subsequent repackaging
into synaptic vesicles to maintain glycinergic neurotransmis-
sion (14). The most potent bioactive lipids bear positively
charged (Lys) or aromatic (Trp) amino acid head groups and
inhibit GlyT2 with IC50 concentrations of less than 50 nM
(13). Within the allosteric-binding site, oleoyl-L-lysine (C18ω9-
L-Lys) orients tail down so that the tail intercalates between
aliphatic-rich regions of TM5 and TM8 and the oleoyl double
bond is in close proximity to TM5 (6). The amino acid head
group is accessible to the extracellular solution and stabilized
by aromatic residues in TM7, TM8, and EL4 (6).
In the present work, we use a combination of medicinal
chemistry, electrophysiology, and computational modeling to
explore the structure–activity relationship for lipid inhibitors
of GlyT2 to understand how head group stereochemistry and
chemical features of the acyl tail affect inhibitor activity and
interaction with GlyT2 at a molecular level. The effects of head
group stereochemistry are investigated for the most potent
previously identified lipid inhibitors, C18ω9-Lys and C18ω9-
Trp. To further understand the effect of structure onJ. Biol. Chem. (2021) 296 100282 1
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Bioactive lipid inhibitors of glycine transporter 2inhibitor potency, a series of acyl-lysine analogs were synthe-
sized with variations in the tail length (C18, C16, and C14) and
position of the double bond within the lipid tail (ω9, ω7, ω5,
and ω3; Fig. 1). Molecular dynamics (MD) simulations were
used to provide a structural basis for the effect of chemical
changes on lipid inhibitor properties. We demonstrate that the
potency of the lipid inhibitors was greatly influenced by a
combination of both the stereochemistry of the head group
and the length and saturation of the lipid tail. Furthermore,
inhibitor potency is shown to depend on deep penetration of
the lipid tail into a stabilized location in the allosteric-binding
site. This study develops a comprehensive structure–activity
relationship for lipid inhibitors of GlyT2. This is critical for
future rational design of more effective GlyT2 inhibitors for
the treatment of chronic pain and may have broader impli-
cations for modulation of other SLC6 transporters.Results
Head group stereochemistry affects C18ω9-Trp binding but
not C18ω9-Lys binding
Bioactive lipids bearing Lys or Trp head groups in the L-
configurations are among the most potent GlyT2 inhibitors in
the series, inhibiting GlyT2 with IC50 concentrations of 25.5
and 54.6 nM, respectively (Table 1). Interestingly, when the
head group is converted to the D-configuration, the Lys analog
(C18ω9-D-Lys) retains potency, whereas the Trp analog
(C18ω9-D-Trp) is inactive (Table 1) (6). To investigate the
molecular basis of this activity, MD simulations of 500 ns were
performed in triplicate, in which one molecule of either the L-
or D-stereoisomers of C18ω9-Lys or C18ω9-Trp was docked
into the extracellular allosteric-binding site of our GlyT2 ho-
mology model (15). Only binding poses in which the lipid tail
was inserted into the extracellular allosteric-binding site and
the double bond was in close proximity to TM5 were
considered (6). Regardless of head group amino acid type or
stereochemistry, the transporter remains in an outward-
occluded conformation (where the intracellular gate distance
is >4.1 Å, and the extracellular gate distance is <14.0 Å;
Table S1) and the membrane properties are not affected by
lipid inhibitor binding (Table S2).
Both C18ω9-L-Lys and C18ω9-D-Lys remain bound in the
allosteric site throughout the combined 1500 ns of MDFigure 1. Chemical structures of GlyT2 lipid inhibitors considered in the pr
2 J. Biol. Chem. (2021) 296 100282simulation with the lipid tail in an extended conformation
(17–20 Å measured from the end of the tail to the stereo-
center; Fig. S1), intercalated between TM5, TM7, and TM8
(Figs. 2A and S2). The amino acid head groups remain in close
proximity to the protein/bilayer–water interface and interact
with the extracellular regions of TM5, TM7, TM8, and EL4,
including hydrogen bonding with cationic arginine residues
(i.e., R439, R531, and R556) and stacking with nonpolar resi-
dues (i.e., F526 and W563). The tail is positioned in a hydro-
phobic pocket lined by L436, V523, Y550, A553, and F567
(Fig. 2B and C), in agreement with previous studies (6). In-
teractions that occur with both the head group and tail are
sustained for >75% of the total simulation time (Table S3).
Notably, the more potent inhibitor, C18ω9-L-Lys, has deeper
penetration into the binding pocket than C18ω9-D-Lys. Y550 is
a key residue in the interaction of both isomers. Y550 interacts
with C18ω9-L-Lys above the oleoyl double bond. The change
of stereochemistry to C18ω9-D-Lys decreases the depth of
penetration of the oleoyl tail and shifts the interaction with
Y550 below the double bond of C18ω9-D-Lys. In this position,
the Y550 hydroxyl forms hydrogen bonds with the backbone of
W563, so that the lipid tail is sandwiched between Y550 and
W563, with W563 interacting directly with the double bond
with a CH–π interaction. The interactions of Y550 and W563
with both isomers correlate with mutagenesis data reporting
that the GlyT2 Y550L and W563L mutants are not inhibited
by C18ω9-L-Lys or C18ω9-D-Lys (6).
In contrast to the lysine-based analogs, the potency of the
bioactive lipids bearing Trp head groups is significantly
impacted by stereochemistry such that the D-isomer is inactive
against GlyT2 (Table 1) (6). In MD simulations, C18ω9-L-Trp
binds to the GlyT2 allosteric site in a similar conformation as
C18ω9-L-Lys. C18ω9-L-Trp is again intercalated between
TM5, TM7, and TM8 with the double bond in close proximity
to TM5 (Figs. 3A and S3). The D-isomer, C18ω9-D-Trp, alters
its orientation around the stereocenter so the C18ω9 tail
points toward EL4, rather than facing the pocket formed by
TM5, TM7, and TM8. While C18ω9-D-Trp still binds to the
GlyT2 extracellular allosteric site, it adopts a much more
curled conformation than C18ω9-L-Trp (13 Å versus 18 Å
measured from the end of the tail to the stereocenter; Fig. S1).
This curled conformation results in a shallower binding
interaction and reduced depth of penetration of C18ω9-D-Trpesent work. All inhibitors were synthesized as enantiopure D- and L-isomers.
Table 1
Activity of acyl-lysine analogs at GlyT2 and GlyT1
Inhibitor
L-Head group stereochemistry D-Head group stereochemistry
IC50 (nM) % Maximal inhibition Activity at GlyT1 IC50 (nM) % Maximal inhibition Activity at GlyT1
C18 ω9 Trp 54.6a 86.2a >10 μMa >10 μMa 14.2a >10 μMa
C18ω9 Lys 25.5a 86.8a >3 μMa 48.3a 91.0a >3 μMa
C16ω7 Lys 66.6 (49.9–88.7) 90.2 ± 2.1 >3 μM 602 (373–856) 96.2 ± 2.1 >3 μM
C14ω5 Lys 703 (414–1250) 96.2 ± 7.3 >3 μM 1380b 79.7 ± 3.6 >3 μM
C18ω5 Lys 67.5 (31.7–143) 81.3 ± 5.1 >3 μM 64.9 (36.3–123) 87.6 ± 3.7 >3 μM
C16ω3 Lys 10.8 (8.37–13.8) 94.9 ± 1.6 >3 μM 699 (343–1480) 91.8 ± 8.6 >3 μM
a Previously published data from Mostyn et al., 2019 (6).
b 95% Confidence interval was not able to be calculated. n = 3 to 7 for all measurements.
Bioactive lipid inhibitors of glycine transporter 2into the extracellular allosteric site, which alters the coordi-
nation of the lipid tail within the binding pocket. Key head
group interactions with R439 and F526 were maintained.
Residues L436, V523, Y550, A553, and L557 that interact with
the lipid tail of C18ω9-D-Lys, C18ω9-L-Lys, and C18ω9-L-Trp
instead form interactions with the head group of C18ω9-D-Trp
(Fig. 3B and C and Table S3). Only one interaction forms with
the C18ω9-D-Trp lipid tail for >75% of the simulation time.
Without these key residues stabilizing the position of the acyl
tail of C18ω9-D-Trp within the binding site, the tail does not
remain bound between TM5, TM7, and TM8 over the course
of the MD simulation as observed for the active lipid in-
hibitors. Instead the lipid tail leaves the allosteric-binding site
and reorients in the solution toward EL4, where it adopts a
variety of conformations. Despite C18ω9-D-Trp remaining
bound in the extracellular allosteric-binding site throughout
the total simulation time and the seemingly favorable inter-
action of the C18ω9-D-Trp head group, no inhibition of GlyT2
is achieved. This indicates that in order for the bioactive lipids
to inhibit GlyT2, the tail must be stabilized within the extra-
cellular allosteric-binding site, positioned between TM5, TM7,
and TM8. This is in agreement with the inability of free amino
acids to cause inhibition (16).
Shortening the tail of acyl-lysine analogs reduces the depth of
penetration and inhibitor potency
The lipid inhibitors described previously contain 18 carbon
acyl tails with a cis-double bond in the Δ9 position (i.e., nine
bonds from the amide linkage to the amino acid head group),
and penetration of the lipid tails into the allosteric site appears
to be a critical determinant of inhibitory activity. To investi-
gate the effect of tail length on GlyT2 inhibitory activity, we
synthesized D- and L-lysine–based inhibitors with truncated
tails. Double bonds were maintained in the Δ9 position, and
overall chain lengths were reduced to C16 or C14 (C16ω7-Lys
and C14ω5-Lys, respectively). The chemical structures of these
new lipids are shown in Figure 1, and their synthesis and
characterization are described in the Supporting information
section. Newly synthesized acyl lysine analogs were then tested
against GlyT2 and also tested for selectivity by testing against
the closely related GlyT1 transporter using two-electrode
voltage clamp electrophysiology (see Table 1 for inhibitory
data).
While C18ω9-L-Lys and C18ω9-D-Lys had similar levels of
activity, head group conformation greatly affected thepotencies of the chain-shortened analogs. C16ω7-L-Lys
inhibited GlyT2 with an IC50 of 66.6 nM, but the corre-
sponding D-isomer was ninefold less potent (IC50 of 602 nm;
Fig. 4B). Further shortening of the tails to Lys C14ω5 produced
a similar preference for L- versus D-, albeit with marked
decrease in the potency compared with the C18 analogs (IC50
concentrations of 770 and 1380 nM for Lys-L-C14ω5 and Lys-
D-C14ω5, respectively; Fig. 4D).
To provide a structural explanation of this difference in
activity with changing tail length, C16ω7 and C14ω5 acyl ly-
sines in the L- and D-configurations were docked to the
extracellular allosteric-binding site, and 500 ns of unrestrained
MD simulations were performed in triplicate. Throughout all
simulations, GlyT2 remains in an outward-occluded confor-
mation, regardless of the tail length of the acyl lysines
(Table S1). The membrane properties are not affected
(Table S2).
MD simulations showed that both C16ω7-L-Lys and
C14ω5-L-Lys remained bound in the allosteric-binding site
throughout the simulation, with the tail positioned between
TM5, TM7, and TM8 (Figs. 5A and S4). The Lys head groups
of both C16ω7-L-Lys and C14ω5-L-Lys remain in close
proximity to the protein/bilayer–water interface, interacting
with the extracellular regions of TM5, TM7, TM8, and EL4.
C16ω7-L-Lys adopts a similar orientation to that observed for
C18ω9-L-Lys, in close proximity to the key binding pocket
residues (Fig. 5B and Table S4). As was observed for C18ω9-
L-Lys, the C16ω7-L-Lys head group interacts with R436 and
F526. Similarly, the L-Lys C16ω7 tail is located between
TM5, TM7, and TM8 in the extracellular allosteric-binding
site where it interacts with L436, V523, Y550, L557, and
F567, and the bottom of the pocket is flanked by V214. As
was the case for C18ω9-L-Lys, Y550 interacts with the lipid
tail just above the double bond of C16ω7-L-Lys. The simi-
larities between the overall orientation and interactions of
C18ω9-L-Lys and C16ω7-L-Lys with key residues in the
binding pocket provide a structural basis for the potent in-
hibition of GlyT2 by both molecules. Further shortening of
the lipid tail to give C14ω5-L-Lys significantly reduces the
depth of the tail penetration into the binding pocket
(Fig. 5A). Furthermore, shortening of the lipid tail dramati-
cally alters C14ω5-L-Lys head group interactions. The
C14ω5-L-Lys head group interacts with the membrane,
forming hydrogen bonds with 1-palmitoyl-2-oleoyl phos-
phatidylcholine (POPC) head groups (Fig. S5). There are noJ. Biol. Chem. (2021) 296 100282 3
Figure 2. A, positions of the Lys C18ω9 lipid inhibitor binding in the
extracellular allosteric-binding pocket of GlyT2. B and C, residues that
interact with (B) C18ω9-L-Lys or (C) C18ω9-D-Lys in representative snapshots
from molecular dynamics simulations of the lipid inhibitors bound in the
allosteric-binding site. Residues that interact with the lipid inhibitor for
>75% or <75% of the total simulation time are in blue or black text,
respectively. Residues are split based on whether the amino acid interacts
with the lipid inhibitor head group (no underline) or tail group (underlined).
Figure 3. A, position of the two Trp C18ω9 lipid inhibitors in the
extracellular allosteric-binding pocket of GlyT2. B and C, residues that
interact with (B) C18ω9-L-Trp or (C) C18ω9-D-Trp in representative snapshots
from molecular dynamics simulations of the lipid inhibitors bound in the
allosteric-binding site. Residues that interact with the lipid inhibitor for
>75% or <75% of the total simulation time are highlighted in blue or black,
respectively. Residues are split based on whether the amino acid interacts
with the lipid inhibitor head group (no underline) or tail group (underlined).
Bioactive lipid inhibitors of glycine transporter 2interactions with the C14ω5-L-Lys head group that persisted
for >75% of the total simulation time (Fig. 5C and Table S4).
In contrast, the tail maintains interactions with key residues
(i.e., L436, V523, Y550, and F567) for >75% of the total
simulation time. In both C14ω5-L-Lys and C16ω7-L-Lys, the
tail only penetrates as deep as F567 (Fig. 5, B and C), which4 J. Biol. Chem. (2021) 296 100282interacts with C6 of C18ω9-L-Lys and C5 of C16ω7-L-Lys.
This change in orientation of C14ω5-L-Lys (IC50 of 703 nm)
relative to C16ω7-L-Lys (IC50 of 66.6 nm) and C18ω9-L-Lys
Figure 4. Inhibitory activity of acyl-lysine analogs at GlyT2. Increasing concentrations of acyl lysine compounds were applied to oocytes expressing WT
GlyT2 transporters. The transport current at each concentration is normalized to the current produced by 30 μM glycine in the absence of inhibitor. For each
panel, the L-isomer is represented by black circles, and the D-isomer is shown as open squares. The curve fits for oleoyl (C18ω9) lysine are also shown as black
(L-) and gray (D-) dashed lines for comparison. A, C18ω5 acyl-lysine. B, C16ω7 acyl-lysine. C, C16ω3 acyl-lysine. D, C14ω5 acyl-lysine. See Table 1 for IC50
values, 95% confidence interval, and sample sizes.
Bioactive lipid inhibitors of glycine transporter 2(IC50 of 25.5 nm) correlates with the dramatic decrease in
GlyT2 inhibition observed for C14ω5-L-Lys.
Onchangeof stereochemistry to the D-configuration,C16ω7-D-
Lys and C14ω5-D-Lys only remain bound in the extracellular
allosteric site for approximately one third (500 ns) of the total
simulation time. This is in contrast to C18ω9-D-Lys, which re-
mains bound throughout the entire simulation. Furthermore,
C16ω7-D-Lys and C14ω5-D-Lys adopt a different conformation in
the extracellular allosteric-binding pocket to C18ω9-D-Lys
(Figs. 6A and S6). Specifically, the C16ω7-D-Lys head group in-
teracts with the head groups of membrane POPC lipids (Fig. S4B)
while maintaining interactions with key GlyT2 residues (F526,
R439, andR556; Fig. 6B andTable S4).While theC16ω7-D-Lys tail
group is positioned in the extracellular allosteric-binding pocket
in a similar orientation to C18ω9-D-Lys and interacts with L436,
V523, Y550, and F567, none of these interactions persist for>75%
of the total simulation time (Fig. 6B and Table S4). The reduced
occupancy and different binding orientation ofC16ω7-D-Lys (IC50
of 602 nm) in the extracellular allosteric-binding site in part
explain the 12-fold reduced potency relative toC18ω9-D-Lys (IC50
of 48.3 nm). In the case of C14ω5-D-Lys, the D-Lys head group
interacts with F526 andR439 in a similarmanner toC18ω9-D-Lys.
However, the C14ω5-D-Lys tail protrudes into the surrounding
membrane where it interacts with POPC at the protein–lipid
interface (Fig. S7). In this orientation, L443 is the only key res-
idue interacting with the lipid tail for>75% of the total simulation
time (Fig, 6C). The lack of interactions and reduced occupancy in
the extracellular allosteric-binding site may in part explain whyC14ω5-D-Lys is not an effective inhibitor of GlyT2 (IC50 of
1380 nm).
The position of the double bond in the lipid tail changes the
activity of acyl-lysine analogs
To assess the effect of the double-bond position on activity,
we synthesized C18ω5-Lys and C16ω3-Lys, which contain cis-
double bonds in the Δ13 position (Fig. 1). Both L- and D-iso-
mers of C18ω5-Lys inhibit GlyT2 with IC50 concentrations of
67.5 and 64.9 nM, respectively (Fig. 4A and Table 1). This
trend is consistent with the results for C18ω9-L-Lys and
C18ω9-D-Lys, where the configuration of the amino acid head
group did not greatly alter the activity. However, when the
length of the acyl chain was decreased to C16, the position of
the double bond produced a marked difference in inhibitory
activity between isomers. Thus, C16ω3-L-Lys is a potent in-
hibitor of GlyT2 (IC50 of 10.8 nM), whereas the corresponding
D-isomer was 65-fold less potent, with an IC50 of 699 nm
(Fig. 4C).
To provide a structural explanation of this difference in
activity with changing tail length, the L- and D-isomers of
C18ω5 and C16ω3 Lys were docked to the extracellular
allosteric-binding pocket and simulated for 500 ns in triplicate.
Regardless of the presence of a bound inhibitor, GlyT2 again
remains in an outward-occluded conformation (Table S1)
throughout the simulations, and the membrane properties are
not affected (Table S2). Both stereoisomers with C18 tails
(C18ω5-L-Lys and C18ω5-D-Lys) remained bound in theJ. Biol. Chem. (2021) 296 100282 5
Figure 5. A, positions of the L-Lys C18ω9, C16ω7, and C14ω5 lipid in-
hibitor binding in the extracellular allosteric-binding pocket of GlyT2.
TM8 is transparent for clarity. B and C, residues that interact with C16ω7-L-
Lys (B) or C14ω5-L-Lys (C) in representative snapshots from molecular dy-
namics simulations of the lipid inhibitors bound in the allosteric-binding
site. Residues that interact with the lipid inhibitor for >75% or <75% of
the total simulation time are in blue or black text, respectively. Residues are
split based on whether the amino acid interacts with the lipid inhibitor head
group (no underline) or tail group (underlined).
Figure 6. A, positions of the D-Lys C18ω9, C16ω7, and C14ω5 lipid in-
hibitor binding in the extracellular allosteric-binding pocket of GlyT2.
For clarity, TM8 is transparent. B and C, residues that interact with C16ω7-D-
Lys (B) or C14ω5-D-Lys (C) in representative snapshots from molecular dy-
namics simulations of the lipid inhibitors bound in the allosteric-binding
site. Residues that interact with the lipid inhibitor for >75% or <75% of
the total simulation time are in blue or black text, respectively. Residues are
split based on whether the amino acid interacts with the lipid inhibitor head
group (no underline) or tail group (underlined).
Bioactive lipid inhibitors of glycine transporter 2allosteric pocket throughout all simulations. The overall
binding conformation and potencies of C18ω5-L-Lys and
C18ω5-D-Lys were similar to that of the C18ω9-L-Lys and
C18ω9-D-Lys (Fig. 7A). The head group interactions with F526,
L443, and R439 are maintained (Figs. 7B and C and S8 and6 J. Biol. Chem. (2021) 296 100282Table S5), and the tails of C18ω5-L/D-Lys are located between
TM5, TM7, and TM8, interacting with the nonpolar residues
(e.g., V214, L436, Y550, L557, and F567) and Y550 interacts
with the lipid tail above the double bond (Fig. 7), giving a
structural basis for their activity.
Figure 7. A, positions of the C18ω9 L-Lys, C18ω5 L-Lys, and C18ω5 D-
Lys lipid inhibitor binding in the extracellular allosteric-binding
pocket of GlyT2. For clarity, TM8 is transparent. B and C, residues that
interact with C18ω5 L-Lys (B) or C18ω5 D-Lys (C) in representative snap-
shots from molecular dynamics simulations of the lipid inhibitors bound
in the allosteric-binding site. Residues that interact with the lipid inhib-
itor for >75% or <75% of the total simulation time are in blue or black
text, respectively. Residues are split based on whether the amino acid
interacts with the lipid inhibitor head group (no underline) or tail group
(underlined).
Bioactive lipid inhibitors of glycine transporter 2Major differences in the binding interactions of the C16
isomers were observed, consistent with their IC50 concentra-
tions. C16ω3-L-Lys, the most potent inhibitor of GlyT2 in this
lipid series, remains bound in the allosteric pocket throughout
the combined MD simulations, whereas C16ω3-D-Lys only
remains bound in the extracellular allosteric-binding pocket
for approximately one-third of the total simulation time. In the
case of C16ω3-L-Lys, the head group interacts with F526, L443,
and R439, as observed for C18ω9-L-Lys (Figs. 8 and S9). Unlike
other inhibitory lipids, the C16ω3-L-Lys tail does not adopt an
extended conformation but instead has a curled conformation
in the allosteric-binding site between TM5, TM7, and TM8.
The curled C16ω3-L-Lys tail interacts with W215, Y550, L557,
F567, and L436 (Fig. 8B and Table S5). The interaction be-
tween C16ω3-L-Lys and W215 is unique and notable because
W215 is directly adjacent to the glycine-binding site and
physically separates the extracellular allosteric site and the
vestibular substrate-binding site. Interactions with W215 may
reflect communication between the extracellular allosteric-
binding site and the vestibular substrate-binding site. This
altered orientation and the interaction with W215 may in part
explain why C16ω3-L-Lys is the most potent lipid inhibitor
identified to date. In contrast, the potency of C16ω3-D-Lys is
65-fold lower (IC50 of 699 nm) than C16ω3-L-Lys. Simulations
of C16ω3-D-Lys in the extracellular allosteric-binding site
show that the head group interacts with the membrane as well
as key amino acids (i.e., R439 and F526, Fig, 8C). The tail does
not bind stably in the allosteric-binding pocket between TM5,
TM7, and TM8 but instead is oriented toward EL4 interacting
with L557 and L436, and it readily dissociates from the binding
site.
Nonpolar residues stabilize lipid inhibitor binding, while the
stabilizing or destabilizing effect of cationic residues depends
on the lipid inhibitor head group
The binding affinity of lipid inhibitors to the allosteric-
binding pocket of GlyT2 is influenced by both the amino
acid head group and the depth of penetration of the lipid tail.
To better understand the overall energetics of lipid inhibitor
binding, the contribution of each amino acid to the relative
binding energy was calculated using the molecular mechanics
Poisson-Boltzmann surface area energy decomposition
scheme. The focus was placed on binding of the most potent
lipid inhibitor, C16ω3-L-Lys. Twenty-three residues were
identified as having a contribution of more than −1 kJ/mol to
C16ω3-L-Lys binding. Twenty of these were nonpolar, and
three were polar (Thr442, Glu536, and Glu459). The polar
residues contributed up to −2.0 kJ/mol to C16ω3-L-Lys bind-
ing. Residues that have the greatest energetic impact on
binding stability are I520 (−4.9 kJ/mol), V519 (−4.7 kJ/mol),
F567 (−4.5 kJ/mol), L557 (−4.5 kJ/mol), L443 (−4.4 kJ/mol),
V523 (−4.4 kJ/mol), and L436 (−4.3 kJ/mol; Fig. 9). With the
exception of V519, these residues are all within 4 Å of C16ω3-J. Biol. Chem. (2021) 296 100282 7
Figure 8. A, positions of the C16ω7 L-Lys, C16ω3 L-Lys, and C16ω3 D-Lys
lipid inhibitor binding in the extracellular allosteric-binding pocket of
GlyT2. For clarity, TM8 is transparent. B and C, residues that interact with
C16ω3 L-Lys 7 (B) or C16ω3 D-Lys (C) in representative snapshots from
molecular dynamics simulations of the lipid inhibitors bound in the
allosteric-binding site. Residues that interact with the lipid inhibitor for
>75% or <75% of the total simulation time are in blue or black text,
respectively. Residues are split based on whether the amino acid interacts
with the lipid inhibitor head group (no underline) or tail group (underlined).
Figure 9. A, energetic contribution (MM–PBSA, kJ/mol) of GlyT2 resi-
dues to C16ω3 L-Lys binding. B, residues that destabilize the complex by
>1.2kJ/mol or residues that stabilize the binding by >2.5 kJ/mol. C, position
of residues that destabilize the complex by >5.0 kJ/mol or residues that
stabilize the binding by >5.0 kJ/mol relative to the C16ω3 L-Lys lipid
inhibitor.
Bioactive lipid inhibitors of glycine transporter 2L-Lys for >80% of the total simulation time (Table S5) and are
mostly located around the lipid tail (Fig. 9C). All residues that
destabilize binding by more than 1.2 kJ/mol are cationic,
whereas all other residues that destabilize binding by 0.1 kJ/8 J. Biol. Chem. (2021) 296 100282mol are charged. R439 is the residue that most significantly
destabilizes binding (10.5 kJ/mol) because of charge repulsion
between the C16ω3-L-Lys head group and the R439 side chain.
To give insight into the effect of the inhibitor structure on
the activity, the overall energetics of C18ω9-L-Lys and C18ω9-
L-Trp binding were also calculated (Fig. 10). The two most
potent inhibitors, C18ω9-L-Lys and C16ω3-L-Lys, have very
similar binding energy decompositions, with nonpolar residues
(V523, L436, I520, F526, and L557) stabilizing binding and
charged amino acid destabilizing binding (R439). Head group
substitution to C18ω9-L-Trp dramatically alters the per-
residue decomposition of the binding energy. All residues
that strongly stabilize C18ω9-L-Trp binding are cationic (R556,
R531, K532, K325, R439, K323, and K321), and all strongly
destabilizing residues are anionic (E372, D329, E552, D322,
and E530). All these residues are positioned on the
Figure 10. Energetic contribution (MM–PBSA, kJ/mol) of GlyT2 residues
to (A) C18ω9-L-Lys and (B) C18ω9-L-Trp binding.
Bioactive lipid inhibitors of glycine transporter 2extracellular surface of protein surrounding the C18ω9-L-Trp
head group. Interestingly, the overall binding energy for
C18ω9-L-Trp (−218.89 ± 25.8 kJ/mol) is greater than that for
the acyl lysine inhibitors (−104.5 ± 21.5 and −110.9 ± 29.5 kJ/
mol for C16ω3-L-Lys and C18ω9-L-Lys, respectively). This
result highlights that while both acyl lysine and acyl trypto-
phan inhibitors can act on GlyT2, the biochemical basis of
inhibitor stabilization in the extracellular allosteric-binding
site differs between compounds.
Discussion
The present work has highlighted that whilst interactions
between GlyT2 and the lipid head group occur, it is the in-
teractions with the lipid tail that are critical for determining
the activity of the lipid inhibitor. This may form the basis for
the potential mechanism of inhibition. The high sequence
conservation of the extracellular allosteric-binding site resi-
dues across SLC6 transporters suggests that this lipid-binding
interaction could be exploited for broader inhibitor design.
The position of the tail in between TM5, TM7, TM8, and EL4
spans both the core domain of the transporter (TM1, TM2,
TM6, TM6, and TM7) and the scaffold domain (TM3, TM4,
TM8, and TM9) (17, 18) and may disrupt the rocking bundle
mechanism of glycine transport. Indeed, the transition be-
tween the outward-occluded state and inward-open state in
the homologous protein LeuT has been shown to involve
substantial conformational change causing the bending of
TM5 and TM7 and the closure of the central vestibule by EL4
(17, 18). MD simulations of the dopamine transporter andserotonin transporter have also identified changes in TM5 as a
first step in this conformational transition (19). To further
explore the impact the inhibitors are having on the overall
protein structure, the hydrogen bonds between each of the
transmembrane helices over the simulations were recorded.
While most interhelical interactions remain undisrupted (i.e.,
TM6–TM2, TM2–TM7, TM3–TM10, TM10–TM11), notable
differences are observed in the interhelical interactions when
active lipid inhibitors are bound (Table S5). In the extracellular
allosteric-binding pocket, TM5 and TM7 interact through a
hydrogen bond between Y430(OH) and T512(Oγ). This
interaction is lost when the active lipid inhibitors are bound
but are undisturbed relative to the control when the inactive
C18ω9-D-Trp is bound. This change in hydrogen bonding
between TM5 and TM7 may be able to modulate the
conformational change required for substrate transport. The
conformations of the extracellular loops and thereby closure of
the central vestibule were also examined. The binding of the
lipid inhibitors changes the conformation of EL4, which in
turn changes how EL4 interacts with the other extracellular
loops. While the interaction between EL4 and EL2 as well as
EL2 and EL6 is preserved, the interaction between EL4 and
EL6 is disrupted when active lipid inhibitors are bound
(Fig. S10). This in turn leads to the loss of a hydrogen bond in
the vicinity of EL6 on the extracellular edges of TM10 (Y627 or
Q630) and TM12 (Y710) and a widening of the gap between
EL4 and EL6, which opens up the central vestibule. This is the
first evidence of allosteric conformational changes induced by
lipid inhibitor binding to GlyT2.
In the present work, we have investigated the impact of
head group stereochemistry and acyl tail structure on the
activity of lipid-based inhibitors of GlyT2. Overall, the lipid
inhibitor head groups remain stabilized in the aromatic cage
formed by R439, F526, W563, and R556, whereas the tail
group penetrated into the cavity to different depths,
depending on inhibitor tail length and double-bond position.
Importantly, longer tail lengths and deeper binding corre-
lated with increased activity. The most potent inhibitor,
C16ω3-L-Lys, has unique interactions with W215, which is
positioned between the extracellular allosteric-binding site
and substrate-binding site. C16ω3-L-Lys has a potency that is
similar to that of the most potent small molecule GlyT2
inhibitor to date (ORG25543; IC50 = 16 nM). The order of
potency of the remaining inhibitors is C18ω9-L-Lys >
C18ω9-L-Trp, C18ω9-D-Lys, C16ω7-L-Lys, C18ω5-L-Lys,
C18ω5-D-Lys > C16ω7-D-Lys, C16ω3-D-Lys, C14ω5-L-Lys >
C14ω5-D-Lys >>> C18ω9-D-Trp. We have shown that the
energetic stabilization of acyl lysine and acyl tryptophan in-
hibitors in the extracellular allosteric-binding site varies
significantly, that overall the L-stereoisomer is typically more
potent than the D-stereoisomer, and the position of the
double bond influences the activity of the inhibitor. We
propose that the formation of this deep binding pocket is
critical for inhibition, and that bioactive lipids that can
penetrate the aliphatic cavity of the extracellular allosteric-
binding site are superior inhibitors. Furthermore, this pro-
vides insight into the mechanism of inhibition of GlyT2 andJ. Biol. Chem. (2021) 296 100282 9
Bioactive lipid inhibitors of glycine transporter 2highlights how lipids can modulate the activity of membrane
proteins by infiltrating pockets between helices, a phenom-
enon that has been similarly proposed in cannabinoid re-
ceptors and cys-loop receptors (20–23). The present work
has provided insight into the structural features of GlyT2
inhibitors that will be important for the future design of
novel inhibitors of GlyT2. The structural basis of inhibitor
activity reported here may provide insights that are appli-
cable to the broader development of new compounds that
could target homologous neurotransmitter transporters, such
as the dopamine, serotonin, and noradrenaline transporters.
Experimental procedures
All N-acyl amino acids were synthesized as previously
described (13). See Supporting Information for full details.
Stock solutions of 10 mg ml−1 of N-acyl amino acids were
dissolved in dimethyl sulfoxide and diluted in frog Ringer’s
solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM
CaCl2, 5 mM Hepes, pH 7.5) to desired concentrations. Final
solutions contained 0.0025% dimethyl sulfoxide, a concentra-
tion that had no effect on transporter or receptor function.
WT and mutant RNA transcription
Human GlyT2a WT complementary DNA was subcloned
into the plasmid oocyte transcription vector. The amplified
GlyT2/plasmid oocyte transcription vector product was then
transformed in Escherichia coli cells and subsequently purified
using the PureLink Quick Plasmid Miniprep Kit (Invitrogen by
Life Technologies) and sequenced by the Australian Genome
Research Facility (Sydney, Australia). The purified plasmid
DNA was linearized via the restriction enzyme, SpeI (New
England Biolabs [Genesearch]) for GlyT2a. Complementary
RNAs were synthesized using the mMESAGE mMACHINE
T7 kit (Ambion).Oocyte preparation and injection
All work involving the use of animals was performed in
accordance with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes. Xenopus laevis
frogs (NASCO) were anesthetized with 0.17% (w/v) 3-amino-
benzoic acid ethyl ester and had an ovarian lobe removed via
an incision in the abdomen. Stage V oocytes were isolated
from the lobe via digestion with 2 mg ml−1 collagenase A
(Boehringer) at 26 C for 1 h, and 20 ng of cRNA encoding
GlyT2 was injected into each oocyte cytoplasm (Drummond
Nanoinject; Drummond Scientific Co). The oocytes were then
stored in frog Ringer’s solution (96 mM NaCl, 2 mM KCl,
1 mMMgCl2, 1.8 mM CaCl2, 5 mM Hepes, pH 7.5), which was
supplemented with 2.5 mM sodium pyruvate, 0.5 mM
theophylline, 50 μg/ml gentamicin and 100 μM ml−1 tetracy-
cline. The oocytes were stored at 18 C for 3 to 5 days, until
transporter expression was adequate for measurement using
the two-electrode voltage clamp technique. Adequate trans-
porter expression was defined as a ≥30 nA current following
application of the glycine EC50.10 J. Biol. Chem. (2021) 296 100282Two-electrode voltage clamp electrophysiology
GlyT2 is electrogenic, allowing activation to be measured
via the two-electrode voltage clamp technique. Oocytes were
voltage clamped at −60 mV, and whole-cell currents generated
by the substrate were recorded with a Geneclamp 500 ampli-
fier (Axon Instruments), digitized by a Powerlab 2/20 chart
recorder (ADInstruments). LabChart version 8 software
(ADInstruments, Axon Instruments) was used to visualize and
process current traces. Recordings were performed in frog
Ringer’s solution. Oocytes were placed in an oval-shaped bath
with a volume of 0.3 ml, with laminar flow around the oocyte
at a rate of 12 ml min−1 under gravity feed.
Each of the synthesized acyl-lysine compounds were first
tested for their inhibitory activity by coapplying the analogs
with 30 μM glycine and assessing their ability to reduce
glycine transport currents. Increasing concentrations of each
acyl-lysine inhibitor were applied to generate concentration
response curves, from which IC50 values and percent
maximal inhibition values were calculated. Acyl-lysines were
also applied to the related transporter GlyT1 to assess their
selectivity and were shown to not significantly inhibit GlyT1
currents at concentrations up to 3 μM. We previously
showed that concentrations of up to 3 μM of oleoyl L-lysine
do not alter uninjected oocytes, and that the critical micelle
concentration of positively charged bioactive lipids is above
this value (13).Computational modeling
Docking and MD simulations were performed using the
protocol developed in our previous work (6). Briefly, each of
the lipid inhibitors was docked to our previously validated
GlyT2 homology model using Autodock vina (24). The lipids
were treated in a united atom representation to be consistent
with the subsequent MD simulations and treated as flexible.
Lipid inhibitors were docked to the previously identified
extracellular allosteric-binding pocket. Following docking, the
pose with the lipid inhibitors bound with the tail inserted into
the extracellular pocket and the double bond in close prox-
imity to TM5 and the protein–lipid interface was considered
for simulation.
The Automated Topology Builder and Repository (25) was
used to develop united atom coordinates and parameters for the
lipid inhibitors (Molecule IDs: 252930, 340331, 252919, 253354,
364924, 364925, 364971, and 364972). To ensure that there was
no isomerization around the cis-double bond, the force constant
related to this dihedral angle in the lipid inhibitors was adjusted
from 5.86 to 41.80 kJ mol−1 rad−2. The protonation state for all
lipids was that in which it would most likely be found at physio-
logical pH (pH 7): POPC and the lipid inhibitors with a Lys head
group were zwitterions, whereas the lipid inhibitors with a Trp
head group were deprotonated. The simulations were performed
using GROMACS, version 2016.1 (26), with the GROMOS 54A7
force field for lipids and proteins (27). GlyT2 was embedding in a
membrane containing 80% POPC and 20% cholesterol, each
system was neutralized, and salt was added to a concentration of
Bioactive lipid inhibitors of glycine transporter 20.15 M NaCl. All systems were minimized using a steepest
descent and equilibrated with decreasing restraints on the protein
in five sequential 1 ns simulations (1000 kJ mol−1 nm−2, 500 kJ
mol−1 nm−2, 100 kJ mol−1 nm−2, 50 kJ mol−1 nm−2, and 10 kJ
mol−1 nm−2). Each systemwas then simulated without constrains
in triplicate for 500 ns. Throughout all simulations, the pressure
wasmaintained at 1 bar using semi-isotropic position scaling and
the Berendsen barostat (τP = 0.5 ps and isothermal compress-
ibility = 4.5 × 10−5 bar), the temperature was maintained at 300 K
using the Bussi–Donadio–Parrinello velocity rescale thermostat
(τP = 0.1 ps), the periodic boundary condition, a 2 fs time step,
SETTLE was used to constrain the geometry of water molecules,
and LINCSwas used to constrain the covalent bond lengths of the
solute. Visualization of the simulations was performed using the
Visual Molecular Dynamics software (28). Analysis was done on
frames spaced by 0.1 ns using gromacs tools andVisualMolecular
Dynamics software.
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